Stellar allowed Uracyst patent in U.S.

Stellar Pharmaceuticals (OTCBB: SLXCF) has received a Notice of Allowance from the U.S. Patent and Trademark Office for intellectual property central to its Uracyst treatment of interstitial cystitis/painful bladder syndrome.  The patent will expire in 2024. The issuance of the patent triggers a milestone payment of $1.3 million (U.S.) from Stellar’s U.S. marketing and distribution [...]

Lorus gets first patent in China

Lorus Therapeutics (TSX:LOR) received allowance of its first patent in China for novel drug candidates from its small molecule program. The Chinese patent covers composition of matter for Lorus’ lead anticancer small molecule LOR-253, as well as composition and uses of its lead antimicrobial compound LOR-220.  Lorus has similar patents pending worldwide for the two [...]

U.S. grants another two patents to GeneNews on Sentinel Principle

GeneNews (TSX:GEN) was granted two new U.S. patents on its core Sentinel Principle platform technology, covering “Biomarkers for Diagnosing Schizophrenia” and “Mild Osteoarthritis Biomarkers and Uses Thereof.” The schizophrenia patent covers any analysis of a blood sample in which the expression pattern of a 9-gene panel is assessed in a diagnosis of schizophrenia.  The mild [...]